<--- Back to Details
First PageDocument Content
Tyrosine kinase receptors / Anatomy / Vascular endothelial growth factor / Angiogenesis inhibitors / Bevacizumab / Ranibizumab / VEGF receptors / Angiogenesis / Lymphangiogenesis / Angiology / Biology / Medicine
Tyrosine kinase receptors
Anatomy
Vascular endothelial growth factor
Angiogenesis inhibitors
Bevacizumab
Ranibizumab
VEGF receptors
Angiogenesis
Lymphangiogenesis
Angiology
Biology
Medicine

Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Download Document from Source Website

File Size: 3,58 MB

Share Document on Facebook

Similar Documents

United States Government Accountability Office  GAO Report to the Ranking Member, Committee on Finance, U.S. Senate

United States Government Accountability Office GAO Report to the Ranking Member, Committee on Finance, U.S. Senate

DocID: 1riEa - View Document

Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri

Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri

DocID: 1qX2r - View Document

References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC

References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC

DocID: 1qSc2 - View Document

CURRICULUM VITAE Mary W. Redman, Ph.D.  Current Address:

CURRICULUM VITAE Mary W. Redman, Ph.D. Current Address:

DocID: 1qCPH - View Document

CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for

CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for

DocID: 1pDeC - View Document